Neil Kumar - 16 Aug 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: BBIO
Reported as of: 16 Aug 2025
Net transaction value: -$1,686,119
SEC form: 4
Accepted by SEC: 19 Aug 2025, 19:38:18 UTC
Prior SEC filing: 18 Aug 2025
Next SEC filing: 22 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Laura Woodhead, Attorney-in-Fact

Key filing fact

Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 19 Aug 2025.

Key facts

This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 19 Aug 2025, 19:38.

Change

Previous filing in this sequence was filed on 18 Aug 2025.
Current net transaction value: -$1,686,119.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742485 Primary reporting owner

Kumar Neil

Relationship: Chief Executive Officer, Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Laura Woodhead, Attorney-in-Fact
Signature date: 19 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Options Exercise

Transaction value
Shares: +64,697
Change %: +30%
Price
Shares after: 282,101
Date: 16 Aug 2025
Ownership: Direct
Footnotes: F1

BBIO transaction

Common Stock

Tax liability

Transaction value: $1,686,119
Shares: -32,855
Change %: -12%
Price: $51.32
Shares after: 249,246
Date: 16 Aug 2025
Ownership: Direct
Footnotes: F2

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,718,447
Date: 16 Aug 2025
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F3

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 915,686
Date: 16 Aug 2025
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -33,544
Change %: -14%
Price: $0.000000
Shares after: 201,264
Date: 16 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,544
Exercise price
Footnotes: F1, F4

BBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -19,599
Change %: -9.1%
Price: $0.000000
Shares after: 195,993
Date: 16 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,599
Exercise price
Footnotes: F1, F5

BBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -11,554
Change %: -6.7%
Price: $0.000000
Shares after: 161,753
Date: 16 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,554
Exercise price
Footnotes: F1, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,697 shares of Common Stock underlying the Reporting Person's RSUs.

Footnote F3

The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Footnote F4

The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Footnote F5

The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Footnote F6

The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.